PI3Kα Covalent Inhibitor Warhead Linker Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors, particularly pan-PI3K inhibitors, exhibit low response rates in clinical trials due to adverse side effects and lack of isoform selectivity, with class I pan-PI3K inhibitors causing rapid increases in glucose and insulin levels, and existing PI3Kα-specific drugs have limited selectivity and efficiency.
Innovation Solution
Development of selective covalently binding inhibitors with a fast-reacting Michael acceptor warhead connected via a linker to a scaffold that forms a covalent bond with a cysteine in the ATP-binding site of PI3Kα, optimizing linker length and warhead reactivity to achieve isoform selectivity and prolonged inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If pan-PI3K inhibitors are used to inhibit PI3K signaling, then broad PI3K pathway inhibition is achieved, but adverse side effects occur due to lack of isoform selectivity
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features (warhead groups, linker lengths, scaffold configurations) that target particular cysteine residues in PI3Kα isoform while sparing other PI3K isoforms. This localized molecular design enables selective inhibition of PI3Kα without affecting PI3Kβ, PI3Kδ, or PI3Kε, thereby achieving isoform-specific therapy that maintains efficacy while reducing adverse side effects associated with pan-PI3K inhibition.
2Strength
If covalent inhibitors with fast-reacting warheads are used to achieve strong binding, then inhibition potency increases, but selectivity decreases due to off-target reactions
Solution Approach 1:
The patent employs parameter changes by systematically optimizing the reactivity parameters of warhead groups (such as acrylamide, vinyl sulfone, or halomethyl ketone groups) and linker properties (length, flexibility, composition). By adjusting these chemical parameters, the invention achieves warheads with moderate reactivity that form covalent bonds efficiently with the target cysteine residue while maintaining sufficient stability to avoid premature reactions with off-target proteins, thus balancing potency and selectivity.
Solution Approach 2:
The patent uses the linker as an intermediary element that connects the warhead group to the scaffold. The linker acts as a spatial mediator that positions the warhead at an optimal distance and orientation relative to the target cysteine residue, enabling selective covalent binding. The linker's structural properties (length, rigidity, flexibility) serve as tunable parameters that mediate between the warhead's reactivity and the scaffold's binding affinity, thereby controlling both potency and selectivity.
3Object-affected harmful factors
If reversible inhibitors are used to avoid covalent modification, then safety improves, but duration of action is insufficient for therapeutic efficacy
Solution Approach 1:
The patent applies dynamics by designing covalent inhibitors that irreversibly modify the target protein, thereby transitioning from transient reversible binding to permanent covalent attachment. This dynamic change in binding mode ensures that once the inhibitor forms a covalent bond with the cysteine residue in PI3Kα, the inhibition is sustained until new protein synthesis occurs, providing prolonged therapeutic action. The covalent bond's stability dynamically ensures long-lasting inhibition while the selective design maintains safety by avoiding off-target covalent modification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in highly potent and selective covalent inhibitors that effectively target PI3Kα, reducing adverse effects and improving isoform selectivity, leading to prolonged inhibition of PI3K signaling and enhanced therapeutic efficacy with reduced off-target interactions.
Implementation Method 1
connecting a first warhead comprising a fast-reacting Michael acceptor moiety to a first scaffold that reversibly inhibits a target protein... determining Kinact of the first and second covalently binding inhibitor with respect to forming a covalent bond to a cysteine
Data Source
AI summary
The invention relates to a method of identifying selective covalently binding inhibitors by using a reversibly inhibiting scaffolds modified by a warhead comprising a fast-reacting Michael acceptor moiety and a linker of different length, determining kinact, and replacing the warhead of the covalently binding inhibitor with the highest kinact by a warhead comprising a moderately reacting Michael acceptor.